354 related articles for article (PubMed ID: 22729222)
21. Identification and Characterization of a Novel Constitutional PIK3CA Mutation in a Child Lacking the Typical Segmental Overgrowth of "PIK3CA-Related Overgrowth Spectrum".
Di Donato N; Rump A; Mirzaa GM; Alcantara D; Oliver A; Schrock E; Dobyns WB; O'Driscoll M
Hum Mutat; 2016 Mar; 37(3):242-5. PubMed ID: 26593112
[TBL] [Abstract][Full Text] [Related]
22. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Higgins MJ; Beaver JA; Wong HY; Gustin JP; Lauring JD; Garay JP; Konishi H; Mohseni M; Wang GM; Cidado J; Jelovac D; Cosgrove DP; Tamaki A; Abukhdeir AM; Park BH
Cancer Biol Ther; 2011 Feb; 11(3):358-67. PubMed ID: 21124076
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum.
Parker VER; Keppler-Noreuil KM; Faivre L; Luu M; Oden NL; De Silva L; Sapp JC; Andrews K; Bardou M; Chen KY; Darling TN; Gautier E; Goldspiel BR; Hadj-Rabia S; Harris J; Kounidas G; Kumar P; Lindhurst MJ; Loffroy R; Martin L; Phan A; Rother KI; Widemann BC; Wolters PL; Coubes C; Pinson L; Willems M; Vincent-Delorme C; ; Vabres P; Semple RK; Biesecker LG
Genet Med; 2019 May; 21(5):1189-1198. PubMed ID: 30270358
[TBL] [Abstract][Full Text] [Related]
24. Clinical and functional characterization of germline PIK3CA variants in patients with PIK3CA-related overgrowth spectrum disorders.
Cooley Coleman JA; Gass JM; Srikanth S; Pauly R; Ziats CA; Everman DB; Skinner SA; Bell S; Louie RJ; Cascio L; Patterson WG; Jones JR; Di Donato N; Stevenson RE; Boccuto L
Hum Mol Genet; 2023 Apr; 32(9):1457-1465. PubMed ID: 36458889
[TBL] [Abstract][Full Text] [Related]
25. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
Mirzaa GM; Rivière JB; Dobyns WB
Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):122-30. PubMed ID: 23592320
[TBL] [Abstract][Full Text] [Related]
26. Somatic activating mutations in
Rodriguez-Laguna L; Agra N; Ibañez K; Oliva-Molina G; Gordo G; Khurana N; Hominick D; Beato M; Colmenero I; Herranz G; Torres Canizalez JM; Rodríguez Pena R; Vallespín E; Martín-Arenas R; Del Pozo Á; Villaverde C; Bustamante A; Ayuso C; Lapunzina P; Lopez-Gutierrez JC; Dellinger MT; Martinez-Glez V
J Exp Med; 2019 Feb; 216(2):407-418. PubMed ID: 30591517
[TBL] [Abstract][Full Text] [Related]
27. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
28. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome.
Kurek KC; Luks VL; Ayturk UM; Alomari AI; Fishman SJ; Spencer SA; Mulliken JB; Bowen ME; Yamamoto GL; Kozakewich HP; Warman ML
Am J Hum Genet; 2012 Jun; 90(6):1108-15. PubMed ID: 22658544
[TBL] [Abstract][Full Text] [Related]
29. Activating PIK3CA somatic mutation in congenital unilateral isolated muscle overgrowth of the upper extremity.
Castiglioni C; Bertini E; Orellana P; Villarroel C; Las Heras F; Hinzpeter D; Paolinelli P; Bevilacqua JA; Alvarez K
Am J Med Genet A; 2014 Sep; 164A(9):2365-9. PubMed ID: 24975390
[TBL] [Abstract][Full Text] [Related]
30. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
31. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
Vahidnezhad H; Youssefian L; Uitto J
Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
[TBL] [Abstract][Full Text] [Related]
32. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
[TBL] [Abstract][Full Text] [Related]
33. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
[TBL] [Abstract][Full Text] [Related]
35. Molecular Diagnosis of Mosaic Overgrowth Syndromes Using a Custom-Designed Next-Generation Sequencing Panel.
Chang F; Liu L; Fang E; Zhang G; Chen T; Cao K; Li Y; Li MM
J Mol Diagn; 2017 Jul; 19(4):613-624. PubMed ID: 28502725
[TBL] [Abstract][Full Text] [Related]
36. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas.
Knobbe CB; Reifenberger G
Brain Pathol; 2003 Oct; 13(4):507-18. PubMed ID: 14655756
[TBL] [Abstract][Full Text] [Related]
37. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
Scrima M; De Marco C; Fabiani F; Franco R; Pirozzi G; Rocco G; Ravo M; Weisz A; Zoppoli P; Ceccarelli M; Botti G; Malanga D; Viglietto G
PLoS One; 2012; 7(2):e30427. PubMed ID: 22363436
[TBL] [Abstract][Full Text] [Related]
38.
Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
[No Abstract] [Full Text] [Related]
39. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
